Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: National Cancer Institute (NCI)
• Treatments: Bleomycin; Dacarbazine; Doxorubicin; Fluorodeoxyglucose F18; Liposomal doxorubicin; Rituximab; Vinblastine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed classical Hodgkin's lymphoma

• No lymphocyte-predominant histology

• Stage II, III, or IV disease

• Newly diagnosed disease

PATIENT CHARACTERISTICS:

• Performance status 0-2

• Creatinine < 2.0 mg/dL

• Bilirubin < 5 mg/dL

• Not pregnant or nursing

• No HIV positivity

• Hepatitis B surface antigen negative

• No active concurrent malignancy except for superficial nonmelanoma skin cancer or cervical carcinoma in situ

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy or radiotherapy for Hodgkin's lymphoma

• Steroids allowed if medically required before chemotherapy initiation